A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge

Gabriella Ferrandina, Francesco Legge, Valentina Mey, Sara Nannizzi, Simona Ricciardi, Marco Petrillo, Giacomo Corrado, Giovanni Scambia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) has been demonstrated to be active in the salvage setting of ovarian cancer (OC) patients. Case report: A 57-year-old woman, with a diagnosis of FIGO Stage IIIC clear cell OC, judged inoperable to optimal residual tumor, was administered neo-adjuvant chemotherapy with carboplatin/paclitaxel/topotecan, and cytoreduction. After 5 months the patient progressed, and pegylated liposomal doxorubicin was started with rapid progression. GEM (1,000 mg/m2, d1,8,15, q28) was then started, and a complete clinical response was documented after seven cycles of treatment, and was maintained for 9 months; at progression fourth line carboplatin was attempted but 1 month after the last course of carboplatin, progression occurred, and the patient was re-challenged with GEM obtaining a partial response, of 6 months duration. Currently, the patient is still under treatment, without any complaints relative to her quality of life/specific symptoms. Conclusion: We described the case of a drug resistant clear cell ovarian cancer showing a selective susceptibility only to GEM at first administration and at re-challenge. Moreover, this case expressed a molecular profile very likely to support high tumour cell sensitivity to GEM.

Original languageEnglish
Pages (from-to)459-461
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume60
Issue number3
DOIs
Publication statusPublished - Aug 2007

Fingerprint

gemcitabine
Air cushion vehicles
Ovarian Neoplasms
Carboplatin
Pharmaceutical Preparations
Tumors
Topotecan
Residual Neoplasm
Adjuvant Chemotherapy
Salvaging
Paclitaxel
Chemotherapy
Quality of Life
Cells
Therapeutics
Neoplasms

Keywords

  • Clear cell ovarian cancer
  • Gemcitabine responsiveness
  • Molecular targets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. / Ferrandina, Gabriella; Legge, Francesco; Mey, Valentina; Nannizzi, Sara; Ricciardi, Simona; Petrillo, Marco; Corrado, Giacomo; Scambia, Giovanni.

In: Cancer Chemotherapy and Pharmacology, Vol. 60, No. 3, 08.2007, p. 459-461.

Research output: Contribution to journalArticle

Ferrandina, Gabriella ; Legge, Francesco ; Mey, Valentina ; Nannizzi, Sara ; Ricciardi, Simona ; Petrillo, Marco ; Corrado, Giacomo ; Scambia, Giovanni. / A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. In: Cancer Chemotherapy and Pharmacology. 2007 ; Vol. 60, No. 3. pp. 459-461.
@article{40faff8a37ee43a0be67ae95357904cd,
title = "A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge",
abstract = "Introduction: Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) has been demonstrated to be active in the salvage setting of ovarian cancer (OC) patients. Case report: A 57-year-old woman, with a diagnosis of FIGO Stage IIIC clear cell OC, judged inoperable to optimal residual tumor, was administered neo-adjuvant chemotherapy with carboplatin/paclitaxel/topotecan, and cytoreduction. After 5 months the patient progressed, and pegylated liposomal doxorubicin was started with rapid progression. GEM (1,000 mg/m2, d1,8,15, q28) was then started, and a complete clinical response was documented after seven cycles of treatment, and was maintained for 9 months; at progression fourth line carboplatin was attempted but 1 month after the last course of carboplatin, progression occurred, and the patient was re-challenged with GEM obtaining a partial response, of 6 months duration. Currently, the patient is still under treatment, without any complaints relative to her quality of life/specific symptoms. Conclusion: We described the case of a drug resistant clear cell ovarian cancer showing a selective susceptibility only to GEM at first administration and at re-challenge. Moreover, this case expressed a molecular profile very likely to support high tumour cell sensitivity to GEM.",
keywords = "Clear cell ovarian cancer, Gemcitabine responsiveness, Molecular targets",
author = "Gabriella Ferrandina and Francesco Legge and Valentina Mey and Sara Nannizzi and Simona Ricciardi and Marco Petrillo and Giacomo Corrado and Giovanni Scambia",
year = "2007",
month = "8",
doi = "10.1007/s00280-007-0479-7",
language = "English",
volume = "60",
pages = "459--461",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge

AU - Ferrandina, Gabriella

AU - Legge, Francesco

AU - Mey, Valentina

AU - Nannizzi, Sara

AU - Ricciardi, Simona

AU - Petrillo, Marco

AU - Corrado, Giacomo

AU - Scambia, Giovanni

PY - 2007/8

Y1 - 2007/8

N2 - Introduction: Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) has been demonstrated to be active in the salvage setting of ovarian cancer (OC) patients. Case report: A 57-year-old woman, with a diagnosis of FIGO Stage IIIC clear cell OC, judged inoperable to optimal residual tumor, was administered neo-adjuvant chemotherapy with carboplatin/paclitaxel/topotecan, and cytoreduction. After 5 months the patient progressed, and pegylated liposomal doxorubicin was started with rapid progression. GEM (1,000 mg/m2, d1,8,15, q28) was then started, and a complete clinical response was documented after seven cycles of treatment, and was maintained for 9 months; at progression fourth line carboplatin was attempted but 1 month after the last course of carboplatin, progression occurred, and the patient was re-challenged with GEM obtaining a partial response, of 6 months duration. Currently, the patient is still under treatment, without any complaints relative to her quality of life/specific symptoms. Conclusion: We described the case of a drug resistant clear cell ovarian cancer showing a selective susceptibility only to GEM at first administration and at re-challenge. Moreover, this case expressed a molecular profile very likely to support high tumour cell sensitivity to GEM.

AB - Introduction: Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) has been demonstrated to be active in the salvage setting of ovarian cancer (OC) patients. Case report: A 57-year-old woman, with a diagnosis of FIGO Stage IIIC clear cell OC, judged inoperable to optimal residual tumor, was administered neo-adjuvant chemotherapy with carboplatin/paclitaxel/topotecan, and cytoreduction. After 5 months the patient progressed, and pegylated liposomal doxorubicin was started with rapid progression. GEM (1,000 mg/m2, d1,8,15, q28) was then started, and a complete clinical response was documented after seven cycles of treatment, and was maintained for 9 months; at progression fourth line carboplatin was attempted but 1 month after the last course of carboplatin, progression occurred, and the patient was re-challenged with GEM obtaining a partial response, of 6 months duration. Currently, the patient is still under treatment, without any complaints relative to her quality of life/specific symptoms. Conclusion: We described the case of a drug resistant clear cell ovarian cancer showing a selective susceptibility only to GEM at first administration and at re-challenge. Moreover, this case expressed a molecular profile very likely to support high tumour cell sensitivity to GEM.

KW - Clear cell ovarian cancer

KW - Gemcitabine responsiveness

KW - Molecular targets

UR - http://www.scopus.com/inward/record.url?scp=34250656618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250656618&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0479-7

DO - 10.1007/s00280-007-0479-7

M3 - Article

VL - 60

SP - 459

EP - 461

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -